Rocket One (RKTO) Total Non-Current Liabilities (2023 - 2024)
Rocket One's (RKTO) quarterly Total Non-Current Liabilities came in at $2709.0 in Q4 2024, down 89.71% year-over-year from $26326.0 in Q1 2024, and little changed quarter-over-quarter from $2709.0 in Q3 2024.
Powered by 
Analysis
Rocket One (RKTO) Total Non-Current Liabilities (2023 - 2024) Analysis & Trends
Rocket One has disclosed Total Non-Current Liabilities across 2 years of filings, most recently posting $2709.0 for Q4 2024.
- In Q4 2024, Total Non-Current Liabilities fell 89.71% year-over-year to $2709.0; the TTM figure through Dec 2024 stood at $2709.0 (down 89.71% YoY), while the FY2024 annual figure was $2709.0, down 89.71% from the prior year.
- Total Non-Current Liabilities came in at $2709.0 for Q4 2024 at Rocket One, roughly flat from $2709.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $26326.0 in Q4 2023 to a low of $2709.0 in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 81.11 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 36.04 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 5.92 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 7.74 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 40.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 3.92 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 12.42 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 378.37 Mn |
| 10 | Rocket One | 13.86 Mn | 5.97 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 2,709.00 |
| Sep 30, 2024 | 2,709.00 |
| Jun 30, 2024 | 11,044.00 |
| Mar 31, 2024 | 18,901.00 |
| Dec 31, 2023 | 26,326.00 |